Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EPS to Take Full Control of EP-Mint in January
October 16, 2014
- Mochida Hooks Up with LG Life Sciences on Adalimumab Biosimilar
October 16, 2014
- Daiichi Sankyo Launches Tender Offer for US Biotech Ambit
October 16, 2014
- FDA OKs World’s 1st Oral Combination Drug for CINV: Helsinn, Eisai
October 16, 2014
- Astellas, Harvard Conduct Joint Research for Retinitis Pigmentosa
October 16, 2014
- Kyorin Licenses Uritos to R-Pharm of Russia
October 15, 2014
- Parexel CEO Hails Rise of Partnership-Based Outsourcing in Japan
October 14, 2014
- Fujifilm’s Overseas Subsidiaries Develop High-Performance Mammalian Expression Platform
October 14, 2014
- Velcade Approved in US for Treatment-Naïve Mantle Cell Lymphoma: Takeda
October 14, 2014
- GSK to Market Authorized Generics through Aspen Japan Unit
October 10, 2014
- Kowa Loses Trademark Suit against Meiji Seika Pharma
October 10, 2014
- Ethical Drug Sales Down 7.2% in August, Switch to Generics Accelerated: Crecon Report
October 10, 2014
- AZ’s US Subsidiary Obtains Exclusive Rights to Shionogi’s Biologic Research Program
October 9, 2014
- Ono Revises Semiannual Forecasts Downward
October 9, 2014
- Shire Japan Takes Aim at $500 Million Sales in 10 Years
October 8, 2014
- Tsumura to Increase Sales of 4 Products in Field of Dermatology by 20% in FY2015
October 8, 2014
- Nipro Pharma Ties Up with Unilab of Philippines as Part of Efforts to Develop Asian Market
October 8, 2014
- Cost-Effective Assessment Could Hamper Patient Access to New Drugs: Chugai CEO
October 7, 2014
- Chugai, Roche Chiefs Were in Talks on Recent Deal Change from 2 Years Ago
October 7, 2014
- Takeda Ordered to Pay Over US$2 Million in Philadelphia Actos Suit
October 7, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…